Biotricity Company Insiders
| BTCY Stock | USD 0.29 0.01 4.92% |
Biotricity employs about 46 people. The company is managed by 8 executives with a total tenure of roughly 19 years, averaging almost 2.0 years of service per executive, having 5.75 employees per reported executive. Break down of Biotricity's management performance can provide insight into the company performance.
| Waqaas AlSiddiq Chairman Founder, Chairman, CEO and Executive Officer |
Biotricity | Build AI portfolio with Biotricity Stock |
Biotricity Management Team Effectiveness
The company has return on total asset (ROA) of (0.1146) % which means that it has lost $0.1146 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (41.0079) %, meaning that it created substantial loss on money invested by shareholders. Biotricity's management efficiency ratios could be used to measure how well Biotricity manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Biotricity's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 4.39 in 2026, whereas Return On Tangible Assets are likely to drop (10.49) in 2026. At this time, Biotricity's Debt To Assets are fairly stable compared to the past year. Asset Turnover is likely to rise to 2.31 in 2026, whereas Total Assets are likely to drop slightly above 4.1 M in 2026.Common Stock Shares Outstanding is likely to rise to about 26 M in 2026, despite the fact that Net Loss is likely to grow to (25.8 M). Biotricity holds a total of 26.57 Million outstanding shares. Biotricity retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Shares in Circulation | First Issued 2014-03-31 | Previous Quarter 26.3 M | Current Value 26.3 M | Avarage Shares Outstanding 11.3 M | Quarterly Volatility 11.3 M |
Biotricity Workforce Comparison
Biotricity is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 211. Biotricity totals roughly 46.0 in number of employees claiming about 22% of equities under Health Care industry.
Biotricity Profit Margins
The company has Profit Margin (PM) of (0.37) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.07 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.07.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.4 | 0.69 |
|
|
Biotricity Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biotricity insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biotricity's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Biotricity insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
John Ayanoglou over two weeks ago Acquisition by John Ayanoglou of 50000 shares of Biotricity at 2.4 subject to Rule 16b-3 | ||
John Ayanoglou over a year ago Acquisition by John Ayanoglou of 50000 shares of Biotricity at 0.73 subject to Rule 16b-3 | ||
David Rosa over a year ago Acquisition by David Rosa of 75930 shares of Biotricity subject to Rule 16b-3 | ||
Waqaas AlSiddiq over a year ago Acquisition by Waqaas AlSiddiq of 350000 shares of Biotricity subject to Rule 16b-3 | ||
John Ayanoglou over a year ago Acquisition by John Ayanoglou of 50000 shares of Biotricity subject to Rule 16b-3 |
Biotricity Notable Stakeholders
A Biotricity stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biotricity often face trade-offs trying to please all of them. Biotricity's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biotricity's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Waqaas AlSiddiq | Founder, Chairman, CEO and Executive Officer | Profile | |
| George Nikopoulos | Director Development | Profile | |
| Fareeha Siddiqui | Executive Solutions | Profile | |
| Amjad Talpur | Senior Operations | Profile | |
| Amir Ali | Chief Officer | Profile | |
| John Ayanoglou | Chief Officer | Profile | |
| Andy Wong | Vice Operations | Profile | |
| Matt Zabel | Vice Strategy | Profile |
About Biotricity Management Performance
The success or failure of an entity such as Biotricity often depends on how effective the management is. Biotricity management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biotricity management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biotricity management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (9.99) | (10.49) | |
| Return On Capital Employed | 4.14 | 4.35 | |
| Return On Assets | (9.99) | (10.49) | |
| Return On Equity | 4.18 | 4.39 |
Please note, the imprecision that can be found in Biotricity's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Biotricity. Check Biotricity's Beneish M Score to see the likelihood of Biotricity's management manipulating its earnings.
Biotricity Workforce Analysis
Traditionally, organizations such as Biotricity use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biotricity within its industry.Biotricity Manpower Efficiency
Return on Biotricity Manpower
| Revenue Per Employee | 299.8K | |
| Revenue Per Executive | 1.7M | |
| Net Loss Per Employee | 183.1K | |
| Net Loss Per Executive | 1.1M |
Additional Tools for Biotricity Stock Analysis
When running Biotricity's price analysis, check to measure Biotricity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotricity is operating at the current time. Most of Biotricity's value examination focuses on studying past and present price action to predict the probability of Biotricity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotricity's price. Additionally, you may evaluate how the addition of Biotricity to your portfolios can decrease your overall portfolio volatility.